Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation plc (NASDAQ: AMRN) announced that icosapent ethyl has been included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines and the Egyptian Heart Journal’s Practical Guidance for lipid management. This recognition signifies growing global support for icosapent ethyl as a treatment option in reducing cardiovascular risk, increasing the total number of endorsing organizations to 15. The CCS recommends its use for patients with atherosclerotic cardiovascular disease and elevated triglyceride levels, highlighting its clinical benefits validated by the REDUCE-IT study.
Amarin Corporation (NASDAQ:AMRN) presented significant findings from its REDUCE-IT STROKE study at the International Stroke Conference 2021. The study demonstrated a 28% reduction in first strokes and a 32% reduction in total strokes with VASCEPA compared to placebo. Notably, ischemic strokes saw a 36% decrease without increasing the risk of hemorrhagic strokes among statin-treated patients with elevated cardiovascular risk. The study won the Paul Dudley White International Scholar Award, highlighting its impactful results for stroke prevention.
Amarin Corporation (NASDAQ:AMRN) reported record annual revenue of $614.1 million for 2020, up 43% from 2019, with Q4 revenue at $167.3 million, a 17% increase year-over-year. This growth was driven by increased use of VASCEPA® (icosapent ethyl) despite COVID-19 challenges. Amarin received a positive CHMP opinion for VAZKEPA® in Europe, expecting formal approval in April 2021. The company ended 2020 with a strong balance sheet, totaling $563.4 million in cash and no debt. Amarin anticipates robust growth in 2021, particularly in the U.S. and international markets.
Amarin Corporation plc (NASDAQ:AMRN) has announced presentations by CEO John F. Thero at two investor conferences: the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 9:20 a.m. ET, and the Cowen 41st Annual Health Care Conference on March 1, 2021, at 10:20 a.m. ET. Live audio webcasts will be available on Amarin's website for 30 days post-event. Amarin is committed to evolving cardiovascular disease management and has grown significantly since its inception in 2009, now employing approximately 1,000 individuals globally.
Amarin Corporation announces a conference call for discussing its fourth quarter and full year 2020 financial results on February 25, 2021, at 7:30 a.m. ET. This follows the anticipated release of financial results earlier that day. Investors can access the call via the company's website or by dialing the designated phone numbers. A replay will be available for two weeks thereafter. Questions can be submitted prior to the call via email, and management will respond to queries during the live session.
Amarin Corporation plc (NASDAQ:AMRN) announced that its partner Edding has initiated regulatory reviews for VASCEPA® (icosapent ethyl) in Mainland China and Hong Kong. The Chinese National Medical Products Administration has accepted VASCEPA's new drug application, with a decision expected by the end of 2021. Concurrently, Hong Kong's Department of Health is reviewing VASCEPA based on prior approvals in the U.S. and Canada. Both parties aim to provide this treatment option, highlighting its significance in combating cardiovascular disease in the region.
Amarin Corporation (NASDAQ:AMRN) announced a positive opinion from the CHMP of the EMA recommending marketing authorization for icosapent ethyl, branded as VAZKEPA, for reducing cardiovascular event risks in high-risk patients. This decision is based on over a decade of research, including the REDUCE-IT study, which showed a 25% relative risk reduction in major cardiovascular events among patients taking the drug. A European Commission decision is expected within 67 days, potentially granting ten years of market protection in the EU and extending exclusivity into 2039 through pending patents.
Amarin Corporation has expanded its patent infringement lawsuit against Hikma Pharmaceuticals to include Health Net, a health insurance provider, in the U.S. District Court in Delaware. The lawsuit claims Health Net has induced pharmacies to dispense Hikma's generic icosapent ethyl capsules, infringing on Amarin's patents for cardiovascular risk reduction. Amarin seeks a permanent injunction against these practices and monetary damages. The company emphasizes the significance of its patents in preventative cardiovascular care and plans to pursue the case vigorously, leveraging proceeds from VASCEPA sales.
Amarin Corporation plc (NASDAQ:AMRN) announced that icosapent ethyl has been included in the updated Guidelines for Primary Prevention of Cardiovascular Diseases by the Chinese Society of Cardiology (CSC) for 2021. The guidelines recommend icosapent ethyl 2 grams twice daily to reduce atherosclerotic cardiovascular disease (ASCVD) risk, highlighting its efficacy as shown in the REDUCE-IT study. With this inclusion, icosapent ethyl is now recognized by 13 medical associations worldwide. The CSC classification reflects strong evidence, underscoring the importance of this treatment for at-risk patients.
Amarin Corporation plc (NASDAQ:AMRN) announced preliminary unaudited total net revenue for 2020 estimated at $610 million, marking a 42% increase from 2019. This growth was primarily driven by increased prescriptions of VASCEPA® despite COVID-19 challenges. The company ended 2020 with over $550 million in cash and no debt. Amarin is preparing for the regulatory approval of VASCEPA in Europe and aims for a commercial launch in 2021. The company plans to present further details at the J.P. Morgan Healthcare Conference on January 12, 2021.